Clarus Ventures names two new partners
This article was originally published in Scrip
Clarus Ventures, a US life sciences venture capital firm, has promoted Dr Emmett Cunninghamto partner and Scott Requadt to transactional partner. Dr Cunningham joined Clarus in 2006 and represents the firm as a director on the board of SARcode and as a board observer at FerroKin, Pearl, Taligen and Zogenix. Mr Requadt joined Clarus in 2005 and represents the firm as a director on the board of TyRx Pharma and as a board observer at Biolex, Oxford Immunotec, Link Medicine and Variation.